Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
Who dares shares.
@tuan6 they should have spent 5 times more to get to where they are now. Biotech is expensive and slow but when it works it makes a lot of dough.
Next time we have to ask Vlad to dance around periodically bursting in songs for HT.
I think the presentation was excellent and to the point. There was not much science or scientific jargon. Vlad made an effort to keep it simple. I was also impressed by his answers to questions. It looks like he is an honest chap.
Amgen halted all BiTE programs, not just FLT3 BiTE (Bispecific T-cell Engager). Amgen is developing FLT3 CAR-T. https://pubmed.ncbi.nlm.nih.gov/32589753/
As far as I know, Amgen is the only company developing CAR-T against FLT3 positive AML.
The difference of HEMO CAR-T is the target on the surface of a cancer cell. This target is FLT3 receptor. CAR-T is an approach to target cancer cells. It is not a drug though. The fact that there are 6-7 approved CAR-T and many in development does tell me that this approach is popular and likely
“Good”. The numbers do not say much about existing competition though.
My understanding is that it was mostly scientific conference. Why would anyone expect any financial activity coming out of that conference?
@hemotruth how do you know who is banging or not banging on Hemo’s door?
HEMO released brilliant annual report that shows enormous progress and a lot of cash in the bank. These achievements were discounted to zero by the market. Why?!? It looks like the market has lost appetite for pre-revenue biotech companies. This is true even in the US. HEMO over its life time raised about 15-16M this is about as much as it’s market value today. This valuation disregards cash in the bank. This valuation has nothing to do with PR. We are in the biotech bust phase. We have to thank Vlad that he managed to preserve cash that will allow HEMO to survive and achieve its goals.
I think you should stop reading Vlad's tweets. Do not give him the pleasure of your attention.
Why are you discussing tweets? What news are you expecting? Hasn't the company announced its actions for the near future? They are working on the pre-IND meeting and then will work on the IND. They are moving into the new facility, establishing manufacturing etc.
Finally, someone @Haywain is trying to understand rather than speculate! This is a good paper by Juno and MSK people.
@hemotruth I hope you are right.
Hemo cannot start clinical trials right away. They have not had a pre-IND meeting yet. A serious biotech company typically present 70-80% of the IND package for a preIND meeting. For Hemo, the missing 30% is manufacturing of CAR-T cells. They have to establish it. They can do it only after they move into their new facility. Process development for CAR-T will most likely take a few months. I think it will take some 6-9 months for Hemo to file a complete IND.
@Hulver As far as I know Delaware is one of 50 US States. Many companies are registered there because it has a very clear and clean set of corporate laws and a low cost of doing business. I am not sure what Vlad is doing but whatever that is, I am almost certain this company you are talking about has nothing to do with HEMO. Otherwise, Hemo would have announced it as it had announced other subs. Vlad has a non-compete agreement as was disclosed when Hemo went public via an RTO in 2017. He must be mad to publicly announce that he is breaking it. Also, Cybernetics is a science studying systems control.
If you Google Vlad's name you will find that he published papers on Neural Networks in vision when he worked at the Institute for NeuroCYBERNETICS in Russia.
https://www.sciencedirect.com/science/article/abs/pii/092523129290047S?via%3Dihub
I guess this is all one needs to keep in mind.
This thing is totally useless for in vivo type experiments.
@Hemotruth
Have you actually read what is written in the link you posted? The lab does not have animal facility. Personnel should be trained, if it is external, or paid for, if it is internal personnel. This think is totally useless for in vivid type experiments.
@JHFH “ grab a few humanised mice, dose them with a virus, cure them with CBR and flog that treatment for just one single viral infection to some Global Co for enough to fund the company for the next few years. ”
This quote is a clear example of pure illiteracy. Vlad cannot do anything with a real virus in his or most other labs including big and small pharma. To work with a real infectious virus, as it was written in the last RNS, HEMO needs access to a special BSL3 facility. There are just a few of them in the US and around the world. One cannot “grab” mice and put them into such facility either. There is a complicated and highly regulated protocol for animal use and transfer.
It looks like they tried to dumb down a very complicated concept. I am actually impressed by how they have done it. Why would I or any other investor need to know details of how CBR is constructed and how it works beyond what they told us in the RNS?
This is a tube welder. It is typically used when one needs to connect a liquid container to another container in a sterile fashion. In Hemo’s case it looks like they connect a bag with blood to some sort of tissue culture vessel/device. I bet it is a step in CAR-T manufacturing.